Cellectricon has appointed Dr. Thomas Nieland, Research Associate Professor at the Biomedical Engineering Department of Tufts University, to its scientific advisory board. Dr. Nieland brings extensive expertise in e.g. bioengineering and functional genomics as applied to neurodegenerative disease, neuropsychiatry and stem cell research to the advisory board.
Dr. Nieland obtained his PhD at the VU University of Amsterdam and currently holds the position of Research Associate Professor at the Biomedical Engineering Department of Tufts University in Boston, MA. Further, he also shares leadership of the Initiative of Neural Science, Disease and Engineering at Tufts University (INSciDE@Tufts). This is an interdisciplinary research center with the mission to accelerate the discovery of therapeutic solutions to brain disease, integrating technological innovations in biomedical engineering with stem cell biology and regenerative medicine.
At Tufts University, Dr. Nieland’s research is focused on human brain disease, in particular on identifying disease mechanisms, targets and drugs to treat autism spectrum disorders, Parkinson’s and Alzheimer’s disease. Previously, Dr. Nieland performed research at Harvard University, MIT, the Broad Institute of Harvard and MIT, Johns Hopkins University, Stanford University and Merck Research Laboratories.
“We are glad to welcome Thomas to our Scientific Advisory Board, where he will bring extensive disease area knowledge and be a key contributor in further enhancing Cellectricon’s CNS disease research.” said Cellectricon’s CEO, Dr. Mattias Karlsson.